Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 9/22/13  and contains information from public web pages and contributions from the ZoomInfo community.

Mr. Joel A. Jessee

Wrong Joel A. Jessee?

Chief Executive Officer and Chief...

Molecular Transfer Inc
202 Perry Parkway
Gaithersburg, Maryland 20877
United States

 
Background

Employment History

Board Memberships and Affiliations

Education

  • Masters degree , biology
    Virginia Tech.
10 Total References
Web References
Molecular Transfer // Gaithersburg, MD
www.moleculartransfer.com, 22 Sept 2013 [cached]
Joel Jessee, Chief Executive Officer and Chief Scientific Officer Joel has been in product development for life science reagents for over thirty years. Prior to founding MTI, Joel was Vice President of R&D at Life Technologies/Invitrogen and at Atto Biosciences. He spent twenty years at LTI where he developed and introduced some of the most well recognized products for transformation, transfection and gene expression. He received a Masters degree in biology from Virginia Tech. Joel is an inventor or co-inventor on numerous patents.
Advisory Board
www.intradigm.com, 20 Oct 2002 [cached]
Mr. Joel JesseeVice President Atto Bioscience
Advisory Board
www.intradigm.net, 1 Aug 2002 [cached]
Mr. Joel JesseeVice President Atto Bioscience
Drug Discovery Japan
www.healthtech.com, 26 June 1999 [cached]
Dr. Joel A. Jessee, Life Technologies, Inc
...
Dr. Joel A. Jessee, Director of R&D, Life Technologies, IncThe selective isolation and expression of genes and gene families is dependent on several novel technologies which have been integrated into a rapid gene discovery platform.The technologies integral to this platform are a rapid cDNA library construction and normalization procedure.These library construction procedures allow for the creation of normalized libraries that have =5 x 106 primary clones and an average insert size of =1.2 Kb.Selective enrichment of genes is accomplished using a magnetic bead technology that enriches genes from cDNA libraries such that after a single enrichment cycle, as many as 80 % of all clones enriched are a specific gene family or gene.The Improved Gene Trapper System requires no ETOH or phenol extraction and is compatible with a 96-well format for high-throughput applications.Depending on the specific gene, as many as 80 % of the clones obtained using these technologies can have the open reading frame of that gene.
Transformation Biosciences Leadership Team
www.transformationbio.com, 26 April 2011 [cached]
Joel Jessee CEO
Former V.P. R&D, Life Technologies/Invitrogen
Other People with the name "Jessee":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304